Latest Content

Among 90 patients with ES-SCLC, all CRS in the outpatient cohort was grade 1, and no patient in any care model was readmitted.

At the 2026 National Summit on Hematologic Cancers, Kate Kennedy, MSN, APRN, flagged decisions where guidelines give nurses and APPs little direction.

Interim AYA-NAV data show most navigation components reached young patients with cancer as designed, though full sessions lagged during treatment.

Kate Kennedy, MSN, APRN, explains how Vanderbilt-Ingram's award-winning APP clinic moved bispecific step-up dosing out of the hospital.

By 26 months, 81% of families of children with B-ALL reported job or marital changes; less frequent maintenance pulses eased expenses only.

Nurses and NPs share how they manage rash, stomatitis, diarrhea, dose holds, cost, and trial eligibility with oral daraxonrasib in pancreatic cancer.

As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.

Nicole Doell, MSN, RN, of Sylvester explains how nurses can address breast cancer misinformation without judgment and share vetted resources.

A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.

Sylvester's Nicole Doell, MSN, RN, discusses how oncology nurses can support patients with breast cancer emotionally, from diagnosis to survivorship.

Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.

Daraxonrasib, tarlatamab, an mRNA melanoma therapy and ivonescimab led ESMO 2026. Tell us which findings you can act on now.

At an Oncology Nursing News roundtable, APPs discussed earlier lifileucel referral, IL-2 dosing, and toxicities that emerge after discharge.